Manufacturer
NOVARTIS PHARMA STEIN AG
Contents
Ruxolitinib
Indication
Myelofibrosis, postessential thrombocythaemia, Myelofibrosis, postpolycythaemia vera, Primary myelofibrosis, Polycythemia vera.
Instruction
May be taken with or without food.
Drug interaction
Increased plasma concentration with strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin, indinavir, itraconazole, lopinavir, ritonavir, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole) and mild or moderate CYP3A4 inhibitors (e.g. ciprofloxacin, erythromycin, amprenavir, atazanavir, diltiazem, cimetidine). Decreased plasma concentration with CYP3A4 inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin). May increase plasma concentration of substances transported by P-glycoprotein and breast cancer resistance protein (e.g. dabigatran, ciclosporin, rosuvastatin, digoxin).
Malaysia
